Purple Historical Financial Ratios
PPBT Stock | USD 2.69 0.05 1.82% |
Purple Biotech is promptly reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.47, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 8.22 will help investors to properly organize and evaluate Purple Biotech financial condition quickly.
Purple |
About Purple Financial Ratios Analysis
Purple BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Purple Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Purple financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Purple Biotech history.
Purple Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Purple Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Purple Biotech sales, a figure that is much harder to manipulate than other Purple Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Purple Biotech dividend as a percentage of Purple Biotech stock price. Purple Biotech dividend yield is a measure of Purple Biotech stock productivity, which can be interpreted as interest rate earned on an Purple Biotech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Purple Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Purple Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.At this time, Purple Biotech's Debt To Equity is comparatively stable compared to the past year.
2024 | 2025 (projected) | Dividend Yield | 0.1 | 0.088 | Price To Sales Ratio | 11.87 | 11.28 |
Purple Biotech fundamentals Correlations
Click cells to compare fundamentals
Purple Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Purple Biotech fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 9.79 | 14.27 | 4.48 | 10.33 | 11.87 | 11.28 | |
Ptb Ratio | 0.0565 | 0.1 | 0.0559 | 0.0591 | 0.0214 | 0.0203 | |
Book Value Per Share | 6.93 | 3.71 | 2.6 | 1.55 | 0.95 | 1.47 | |
Free Cash Flow Yield | (2.73) | (2.25) | (6.47) | (9.86) | (20.42) | (19.39) | |
Operating Cash Flow Per Share | (1.05) | (0.86) | (0.93) | (0.9) | (0.41) | (0.44) | |
Stock Based Compensation To Revenue | 0.77 | 1.27 | 2.65 | 9.58 | 11.01 | 8.22 | |
Capex To Depreciation | 0.66 | 0.5 | 1.13 | 0.0152 | 0.0175 | 0.0166 | |
Pb Ratio | 0.0565 | 0.1 | 0.0559 | 0.0591 | 0.0214 | 0.0203 | |
Ev To Sales | 4.63 | 10.11 | (5.87) | (61.88) | (71.16) | (67.6) | |
Free Cash Flow Per Share | (1.07) | (0.86) | (0.94) | (0.9) | (0.41) | (0.44) | |
Roic | 0.0689 | (0.28) | (0.49) | 0.6 | (0.33) | (0.35) | |
Net Income Per Share | (2.43) | (1.05) | (1.2) | (8.98E-4) | (0.21) | (0.22) | |
Payables Turnover | 4.8E-5 | 3.7E-5 | 5.6E-5 | 0.0555 | 0.0499 | 0.0524 | |
Research And Ddevelopement To Revenue | 5.27 | 2.67 | 7.49 | 87.0 | 78.3 | 82.21 | |
Capex To Revenue | 0.016 | 0.011 | 0.16 | 0.0153 | 0.0176 | 0.0167 | |
Cash Per Share | 5.03 | 2.69 | 1.78 | 0.7 | 0.25 | 0.23 | |
Pocfratio | (0.37) | (0.45) | (0.16) | (0.1) | (0.049) | (0.0514) | |
Interest Coverage | 206.75 | (84.59) | (179.39) | (268.41) | (241.57) | (253.65) | |
Capex To Operating Cash Flow | (0.0129) | (0.007631) | (0.0136) | (1.51E-4) | (1.73E-4) | (1.82E-4) | |
Pfcf Ratio | (0.37) | (0.44) | (0.15) | (0.1) | (0.049) | (0.0514) | |
Days Payables Outstanding | 7.5M | 9.8M | 6.5M | 6.6K | 7.6K | 7.2K | |
Income Quality | 0.43 | 0.85 | 0.77 | 1.0 | 1.97 | 2.07 | |
Roe | (0.35) | (0.28) | (0.46) | (5.81E-4) | (0.22) | (0.23) | |
Ev To Operating Cash Flow | 0.49 | 0.22 | 0.71 | 0.61 | 0.45 | 0.48 | |
Pe Ratio | (0.16) | (0.37) | (0.12) | (101.7) | (0.0972) | (0.1) | |
Return On Tangible Assets | (0.44) | (0.37) | (0.64) | (0.001223) | (0.79) | (0.83) | |
Ev To Free Cash Flow | (1.81) | 0.48 | 0.22 | 0.7 | 0.61 | 0.45 | |
Earnings Yield | (6.25) | (2.72) | (8.27) | (0.009833) | (10.29) | (9.77) | |
Intangibles To Total Assets | 0.24 | 0.29 | 0.38 | 0.63 | 0.75 | 0.79 | |
Net Debt To E B I T D A | 0.36 | 0.58 | 0.68 | 0.64 | 1.02 | 0.53 | |
Current Ratio | 19.14 | 11.41 | 4.71 | 2.2 | 2.23 | 2.12 | |
Tangible Book Value Per Share | 5.15 | 2.54 | 1.46 | 0.28 | 0.15 | 0.14 | |
Shareholders Equity Per Share | 6.9 | 3.69 | 2.59 | 1.55 | 0.95 | 1.45 | |
Debt To Equity | 0.0113 | 0.0116 | 0.011 | 0.0103 | 0.005569 | 0.005848 | |
Capex Per Share | 0.0136 | 0.006546 | 0.0126 | 1.36E-4 | 1.22E-4 | 1.16E-4 | |
Graham Net Net | 0.0925 | 4.71 | 2.4 | 1.36 | 0.24 | 0.13 | |
Revenue Per Share | 0.0704 | 0.0516 | 0.087 | 0.008847 | 0.007962 | 0.007564 | |
Interest Debt Per Share | 0.0831 | 0.0547 | 0.0355 | 0.0159 | 0.006464 | 0.006141 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.